David Dai

Stock Analyst at UBS

(0)
# 5023
Out of 5,441 analysts
29
Total ratings
Success rate
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
SNDX Syndax Pharmaceutica...
Maintains: Buy
37 35
12.5 180% 2 Jul 15, 2025
NRIX Nurix Therapeutics
Maintains: Buy
30 26
9.64 169.71% 2 Jul 10, 2025
SMMT Summit Therapeutics
Initiates Coverage On: Buy
30
28.23 6.27% 1 Jul 1, 2025
BPMC Blueprint Medicines
Maintains: Neutral
88 129
129.46 -0.36% 2 Jun 5, 2025
IOVA Iovance Biotherapeut...
Downgrades: Neutral
17 2
1.97 1.52% 2 May 16, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
30 24
7.09 238.5% 2 May 12, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
100 100
74.98 33.37% 2 Mar 14, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
27 14
5.54 152.71% 2 Mar 6, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Sell
24
31.9 -24.76% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
20
3.72 437.63% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
72
64.6 11.46% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
69
22.68 204.23% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
50
22.84 118.91% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
60
23.91 150.94% 1 Oct 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Feb 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
0.6 4566.67% 1 Mar 31, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
21.27 88.06% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
1.47 2621.09% 1 Feb 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
2 2400% 1 Nov 18, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
41 52
31.19 66.72% 1 Mar 17, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
41
n/a n/a 1 Apr 25, 2017